Explore this test

  • Test Details
  • Lab Values
  • Clinical Significance
  • Treatment Options
DOWNLOAD SPECIMEN PREP FLYER

Explore this test

Test Code 887

Test Details

Haptoglobin Genotype Test

This test identifies individuals with diabetes or advanced kidney disease who may benefit from vitamin E supplementation. Those individuals with the haptoglobin 2/2 variant are at risk for accelerated oxidative damage due to delayed clearance of haptoglobin-hemoglobin complexes. Vitamin E supplementation (400 IU daily) in those individuals has been demonstrated to reduce the risk of CVD events and CVD death.

Methodology

Real time polymerase chain reaction (PCR)

Patient Preparation

None

Preferred Specimen

1.0 mL whole blood collected in EDTA (Lavender Top)

Alternate Specimen

None

Transport Temperature

Refrigerated (ship on frozen cold packs)

Stability

Refrigerated: 14 days

Lab Values

Lab Values

Haptoglobin Genotype Test

Optimal

  • Genotype 1/1
  • Genotype 1/2

Increased risk

  • Genotype 2/2
Test Details
Clinical Significance

Clinical Significance

Haptoglobin Genotype Test

No increased CVD risk other than from risk associated with underlying conditions

  • Genotype 1/1
  • Genotype 1/2

3-Fold increased CVD risk in patients with diabetes or kidney disease1

  • Genotype 2/2

References:

  1. Cahill LE, Levy AP, Chiuve SE, et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol 2013; 61:728–37.
Lab Values
Treatment Options

Treatment Options

Haptoglobin Genotype Test

Genotype 2/2

Risk may be significantly reduced with 400 units of vitamin E daily given after a meal.1

References:

  • Asleh R, et al. Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation. Pharmgenomics Pers Med. 2018;11:71-82.
Clinical Significance